Did you mean :
Small deal for IBA, huge step for Elysia
During the official inauguration of the CRC RadioMed, Elysia and IBA announced the signature of a collaboration contract. The contract was signed by Francois Moonen (CEO – Elysia) and Bruno Scutnaire (Vice President – IBA RadioPharma Solutions) in presence of the Wallonia minister of economy Jean-Claude Marcourt and Pierre Mottet, Chairman of the IBA Board. This contract will give Elysia access to the IBA network and accelerate the international sales. Elysia will develop and deliver quality
/en/news/4_small-deal-for-iba-huge-step-for-elysia
MUCHA Nova -
analysis in a centralized SQL Database.MUCHA Nova is dedicated to radionuclides identification
during radiopharmaceutical quality control (verification of radioisotope energy peak) and quantitative determination of radio-contaminants coming from cyclotron
/en/cataloglight/mucha-nova~039ace3a-49b8-4312-b730-cc77e3ca812c
GINA X CDS - Centralized Data Solution -
Elysia - Products & Software Software Chromatography Software Products & Software Software Spectroscopy Software - GINA X is a data acquisition and evaluation software for different analytical instruments used
during quality control of radiopharmaceuticals. Simply collect all data from typical Quality Control steps like radiochemical purity, residuals measurement, pH, endotoxin or radio-isotopic purity. Data from instruments such as Radio chromatographs (HPLC & TLC), GC, MCA, LAL and dose
/en/cataloglight/gina-x-cds-centralized-data-solution~1184f072-d33f-86aa-b445-39f9f3d5688f
ECOS -
produced requires its specific HPLC column for quality control by radio-HPLC, which requires frequent column installation/uninstallation cycle. Radio-HPLC run time may vary from 5-6 minutes to more than 30 minutes, in addition,
during development
/en/cataloglight/ecos~b6aebf6f-4fa1-a8d9-ee95-39e9890b29ad
Elysia, the start-up that has become a world leader
Based in Sart-Tilman, Elysia offers solutions for measuring the radioactivity and quality control of radio-pharmacy products to the nuclear medicine departments of hospitals around the world. Thanks to the acquisition of a German competing company, one year after its creation, this start-up has become a world leader in its field! With the aging of the population, cases of cancers detected each year will become more numerous, explains François Moonen, co-founder of Elysia.
During the medical
/en/news/1_elysia-the-start-up-that-has-become-a-world-leader